Nl-Fr

View abstract

Presentation preference Poster and Rapid fire
TitleSafety and factors of efficacy of hypotensive therapy in pediatric uveitic glaucoma
PurposeTo analyze safety and factors of efficacy of hypotensive therapy in pediatric uveitic glaucoma (UG).
Methods178 eyes of 104 children aged from 2 to 15 years (mean 8.7) with open angle or combined with peripheral anterior synechiae forms of UG were treated with topical beta-blockers, carbonic-anhydrase inhibitors, brimonidine and in remission of uveitis – with prostaglandin analogs. Anterior uveitis - 112 eyes, intermediate - 49, posterior - 3, panuveitis - 14; phakic - 118, pseudophakic - 34, aphakic - 26; remission of uveitis - in 116 eyes.
ResultsDuration of IOP compensation before primary hypotensive operation varied from 1 to 86 months (median 11). Factors, associated with failure, were anterior uveitis (vs. intermediate) (p=0.03), pseudophakic or aphakic eye (vs. phakic) (p=0.03, p=0.001 respectively), active uveitis vs. remission (tendency p=0.13). Frequency of topical steroid (3 and more drops a day vs. less than 3) had no influence on treatment efficacy. Local or systemic side effects were detected in 14.3% cases and included bradycardie 1.9%, bronchial asthma exacerbation 1.9% (beta-blockers), drowsiness 3.9% (brimonidine), burning and redness 4.8% (prostaglandin analogs).
ConclusionConventional hypotensive therapy is safe (with best profile for carbonic-anhydrase inhibitors), especially effective in intermediate uveitis, in phakic eyes and in remission of uveitis, and should be considered as first step in treatment of open angle or combined forms of pediatric UG.
Conflict of interestNo
Author 1
Last nameDENISOVA
Initials of first name(s)E.
DepartmentHelmholtz Research Institute of Eye Diseases
CityMoscow
CountryRussian Federation
Author 2
Last nameKatargina
Initials of first name(s)L.
DepartmentHelmholtz Research Institute of Eye Diseases
CityMoscow
CountryRussian Federation
Author 3
Last nameIbaid
Initials of first name(s)B.N.
DepartmentHelmholtz Research Institute of Eye Diseases
CityMoscow
CountryRussian Federation